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Background
Lung cancer is the largest contributor to mortality from cancer. The National Lung 
Screening Trial (NLST) showed that screening with low-dose helical computed to-
mography (CT) rather than with chest radiography reduced mortality from lung 
cancer. We describe the screening, diagnosis, and limited treatment results from 
the initial round of screening in the NLST to inform and improve lung-cancer–
screening programs.
Methods
At 33 U.S. centers, from August 2002 through April 2004, we enrolled asymptom-
atic participants, 55 to 74 years of age, with a history of at least 30 pack-years of 
smoking. The participants were randomly assigned to undergo annual screening, 
with the use of either low-dose CT or chest radiography, for 3 years. Nodules or 
other suspicious findings were classified as positive results. This article reports 
findings from the initial screening examination.
Results
A total of 53,439 eligible participants were randomly assigned to a study group 
(26,715 to low-dose CT and 26,724 to chest radiography); 26,309 participants 
(98.5%) and 26,035 (97.4%), respectively, underwent screening. A total of 7191 par-
ticipants (27.3%) in the low-dose CT group and 2387 (9.2%) in the radiography 
group had a positive screening result; in the respective groups, 6369 participants 
(90.4%) and 2176 (92.7%) had at least one follow-up diagnostic procedure, includ-
ing imaging in 5717 (81.1%) and 2010 (85.6%) and surgery in 297 (4.2%) and 121 
(5.2%). Lung cancer was diagnosed in 292 participants (1.1%) in the low-dose CT 
group versus 190 (0.7%) in the radiography group (stage 1 in 158 vs. 70 participants 
and stage IIB to IV in 120 vs. 112). Sensitivity and specificity were 93.8% and 73.4% 
for low-dose CT and 73.5% and 91.3% for chest radiography, respectively.
Conclusions
The NLST initial screening results are consistent with the existing literature on 
screening by means of low-dose CT and chest radiography, suggesting that a reduc-
tion in mortality from lung cancer is achievable at U.S. screening centers that have 
staff experienced in chest CT. (Funded by the National Cancer Institute; NLST 
ClinicalTrials.gov number, NCT00047385.)
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Lung cancer is the largest single cause of deaths from cancer in the world1-3 and is expected to account for more than 
160,000 deaths in the United States during 2013.4 
Most patients with lung cancer have smoked 
cigarettes.5 Of 94 million U.S. smokers, half are 
former smokers whose risk remains elevated de-
cades after cessation.6
In the National Lung Screening Trial (NLST) 
of screening for lung cancer in older persons who 
were heavy smokers,7 mortality from lung can-
cer was lower with the use of 3 years of annual 
screening with low-dose helical computed to-
mography (CT) than with the use of chest radi-
ography.8 In addition, the Prostate, Lung, Colorec-
tal, and Ovarian Cancer Screening Trial (PLCO)9 
showed that among approximately 30,000 par-
ticipants with baseline characteristics that were 
similar to those of the NLST participants, mor-
tality from lung cancer did not differ signifi-
cantly between participants undergoing screen-
ing by means of chest radiography and those 
receiving usual care,10 confirming the results of 
previous randomized trials of screening with the 
use of chest radiography.11-13
The NLST, a joint effort of the Lung Screen-
ing Study (LSS) and the American College of Ra-
diology Imaging Network (ACRIN), both funded 
by the National Cancer Institute (NCI), began 
randomly assigning participants in August 2002 
to annual screening for 3 years with the use of 
either low-dose CT or chest radiography. Details 
of the study design7 and the rationale for choos-
ing chest radiography as the control procedure14 
have been published previously. A better under-
standing of the screening process, including the 
frequency and management of positive screening 
results, can inform the implementation of lung-
cancer screening programs as well as efforts to 
improve them. Here, we describe the screening, 
diagnosis, and limited treatment results from 
the initial round of screening in the NLST.
Me thods
Study Participants and Study Conduct
At 33 screening centers, we recruited asymptom-
atic men and women, 55 to 74 years of age, who 
had a history of at least 30 pack-years of cigarette 
smoking and who were either current smokers or 
had been smokers within the previous 15 years. 
Participants were randomly assigned to undergo 
annual screening for 3 years with the use of ei-
ther low-dose CT or chest radiography. The study 
was approved by the institutional review board at 
each study center, and all participants provided 
written informed consent before undergoing ran-
domization. Details of recruitment and random-
ization methods have been published previously.7
Screening Equipment and Procedures
Low-dose CT was performed on multidetector 
helical CT scanners of four or more channels. 
Single-view posteroanterior chest radiographs 
were obtained with the use of conventional film 
or digital radiographic systems. Technical stan-
dards and acquisition variables for both low-dose 
CT and chest radiographic screening have been 
published previously.7,15-17
Image Interpretation
Results were recorded on forms developed for 
the study. The screening image was classified as 
diagnostic, limited but diagnostic, or nondiagnos-
tic, with the reasons documented.
For low-dose CT, all noncalcified nodules with 
long-axis diameters of 4 mm or greater in the 
axial plane were considered to be positive for 
potential lung cancer. For all positive nodules, 
the anatomical location (lobe), longest axial, per-
pendicular diameters, margin characteristics, at-
tenuation, and representative slice number were 
recorded.
For chest radiography, the results were read 
on original film or digital image. All noncalci-
fied nodules and masses were considered to be 
potentially positive for lung cancer, and for all 
positive nodules, the anatomical location, longest 
perpendicular diameters, and margin character-
istics were recorded.
The interpreting radiologist judged whether 
the screening results were positive on the basis 
of findings such as noncalcified hilar or medi-
astinal adenopathy, atelectasis, and pleural dis-
ease. Available historical images were reviewed, 
and all results and recommendations were re-
corded. Screening results were classified as posi-
tive, negative with clinically significant abnor-
malities, negative with minor abnormalities, or 
negative with no abnormality. Participants with-
out diagnostic results were considered to be 
unscreened. Although the NLST had guidelines 
for the follow-up of positive screening results, 
radiologists could make diagnostic recommen-
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dations as they saw fit. Screening results were 
reported to the participant and the participant’s 
designated health care provider, by mail, within 
4 weeks.
Follow-up of Study Participants
All participants were mailed annual question-
naires (for the LSS participants) or semiannual 
questionnaires (for the ACRIN participants) as-
certaining vital status and interim cancer diag-
noses. Among participants with positive screen-
ing results or with a diagnosis of lung cancer, all 
related diagnostic procedures, complications (not 
reported here), and results were abstracted by 
certified medical-record abstractors.
For cases of diagnosed lung cancer, the his-
tologic type and grade, tumor stage,18 and initial 
treatment were documented. To augment the 
ascertainment of deaths from questionnaires, the 
National Death Index was also searched through 
December 31, 2007. Determination of the cause 
of death led to the discovery of some previously 
unreported cases of lung cancer, which were 
also abstracted.
Here, we describe the results of the first 
round of screening and diagnostic evaluations 
that were initiated on the basis of positive find-
ings at the screening visit, as well as all cancers 
diagnosed and treatments initiated at any time 
after randomization until the second screening, 
if applicable, or until 1 year after the first screen-
ing. A diagnostic evaluation consisted of a se-
ries of diagnostic procedures with no more than 
12 months between consecutive procedures, in-
cluding the first screening.
Statistical Analysis
We compared the two screening groups with re-
spect to adherence of the participants to the test-
ing protocol, image quality, types of diagnostic 
procedures, and results (positive or negative 
screening result, ultimate diagnosis, and initial 
treatment information). The results were strati-
fied according to group and, in some cases, age, 
sex, race, educational level, and smoking history. 
All tabulations were performed with the use of 
SAS/STAT software, version 9.1 of the SAS Sys-
tem for Unix or version 9.2 for PC (SAS Institute).
Each screening result was judged to be posi-
tive or negative, and a strict algorithm was used 
to ascertain whether lung cancer was present at 
the time of screening (see details in the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org). Confidence intervals 
were calculated by means of bootstrapping.19
R esult s
Recruitment and Randomization
From August 2002 through April 2004, a total of 
53,454 participants were enrolled at 33 sites 
across the United States; 26,722 were randomly 
assigned to low-dose CT and 26,732 to chest ra-
diography. Figure 1 shows the follow-up of par-
ticipants during the trial.20 A total of 8 partici-
pants had lung cancer and 7 died before the first 
scheduled screening. Of the remaining 53,439 
participants, 26,715 were in the low-dose CT 
group and 26,724 were in the radiography group.
Screening
The first scheduled screening examination was 
performed in 98.0% of the participants (52,344 
of 53,439) — specifically, in 98.5% of the partici-
pants in the low-dose CT group (26,309 of 26,715) 
and in 97.4% of those in the chest radiography 
group (26,035 of 26,724) (Table 1). Compliance 
did not differ significantly according to sex, age, 
race or ethnic group, smoking status, or educa-
tional level (Table 1, and Table 1 in the Supple-
mentary Appendix). Four participants undergo-
ing low-dose CT and 13 participants undergoing 
chest radiography had nondiagnostic results, 
none of whom received a diagnosis of lung can-
cer during the follow-up period. The proportion 
of participants with positive screening results 
was higher in the low-dose CT group (7191 of 
26,309 participants [27.3%]) than in the radiog-
raphy group (2387 of 26,035 [9.2%]). Rates of 
positivity increased slightly with older age and a 
larger number of pack-years of smoking in both 
screening groups.
The proportion of all screened participants 
who had negative screening results but poten-
tially clinically significant, noncancerous abnor-
malities was higher in the low-dose CT group 
(2695 of 26,309 [10.2%]) than in the radiography 
group (785 of 26,035 [3.0%]).
Screening Accuracy
During the baseline follow-up period, lung can-
cer was diagnosed in 292 of the 26,309 partici-
pants (1.1%) who underwent low-dose CT screen-
ing versus 190 of the 26,035 participants (0.7%) 
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who underwent radiographic screening (Fig. 1); 
2 cases of lung cancer in each group were first 
reported in the National Death Index. In the low-
dose CT group, 270 (92.5%) of the participants 
with lung cancer had a positive screening result 
(a true positive result), 18 (6.2%) had a negative 
screening result (a false negative result), and 4 
(1.4%) missed the screening visit. In the radiog-
raphy group, 136 (71.6%) of the participants with 
lung cancer had a positive screening result (a true 
positive result), 49 (25.8%) had a negative screen-
ing result (a false negative result), and 5 (2.6%) 
missed the screening visit. The sensitivity and 
specificity were 93.8% (270 of 288; 95% confi-
dence interval [CI], 90.6 to 96.3) and 73.4% 
(19,043 of 25,954; 95% CI, 72.8 to 73.9), respec-
Table 1. Baseline Characteristics of the Study Participants, According to Study Group.*







All participants 26,715 26,309 (98.5) 7191 (27.3) 26,724 26,035 (97.4) 2387 (9.2)
Sex
Male 15,765 15,539 (98.6) 4194 (27.0) 15,758 15,400 (97.7) 1504 (9.8)
Female 10,950 10,770 (98.4) 2997 (27.8) 10,966 10,635 (97.0) 883 (8.3)
Age
≤54 yr 2 2 (100) 1 (50.0) 4 4 (100) 0
55–59 yr 11,436 11,245 (98.3) 2730 (24.3) 11,417 11,103 (97.2) 870 (7.8)
60–64 yr 8,168 8,059 (98.7) 2217 (27.5) 8,196 7,975 (97.3) 747 (9.4)
65–69 yr 4,755 4,689 (98.6) 1456 (31.1) 4,760 4,661 (97.9) 480 (10.3)
70–74 yr 2,353 2,313 (98.3) 787 (34.0) 2,344 2,289 (97.7) 289 (12.6)
≥75 yr 1 1 (100) 0 3 3 (100) 1 (33.3)
Smoking status†
Former smoker
0 to <30 pack-yr 4 4 (100) 0 11 11 (100) 0
30 to <35 pack-yr 1,824 1,798 (98.6) 433 (24.1) 1,905 1,859 (97.6) 140 (7.5)
35 to <40 pack-yr 2,043 2,010 (98.4) 518 (25.8) 1,966 1,926 (98.0) 172 (8.9)
40 to <45 pack-yr 1,813 1,802 (99.4) 491 (27.2) 1,761 1,728 (98.1) 162 (9.4)
45 to <50 pack-yr 1,423 1,407 (98.9) 394 (28.0) 1,354 1,325 (97.9) 122 (9.2)
≥50 pack-yr 6,749 6,645 (98.5) 1791 (27.0) 6,832 6,666 (97.6) 608 (9.1)
Total 13,856 13,666 (98.6) 3627 (26.5) 13,829 13,515 (97.7) 1204 (8.9)
Current smoker
0 to <30 pack-yr 2 2 (100) 0 4 4 (100) 1 (25.0)
30 to <35 pack-yr 1,099 1,081 (98.4) 251 (23.2) 1,152 1,117 (97.0) 93 (8.3)
35 to <40 pack-yr 1,859 1,834 (98.7) 453 (24.7) 1,869 1,820 (97.4) 131 (7.2)
40 to <45 pack-yr 2,394 2,353 (98.3) 646 (27.5) 2,304 2,232 (96.9) 200 (9.0)
45 to <50 pack-yr 1,549 1,523 (98.3) 444 (29.2) 1,585 1,534 (96.8) 172 (11.2)
≥50 pack-yr 5,956 5,850 (98.2) 1770 (30.3) 5,981 5,813 (97.2) 586 (10.1)
Total 12,859 12,643 (98.3) 3564 (28.2) 12,895 12,520 (97.1) 1183 (9.4)
* Participants 54 years of age or younger and those 75 years of age or older at enrollment were ineligible for the study, as 
were those with less than 30 pack-years of smoking, but data for them were included in the intention-to-treat analysis.
† Former smokers were participants who reported having quit tobacco use; current smokers were participants who re-
ported that they were currently using tobacco.
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tively, for low-dose CT and 73.5% (136 of 185; 
95% CI, 67.2 to 79.8) and 91.3% (23,547 of 25,790; 
95% CI, 91.0 to 91.6), respectively, for chest radi-
ography.
In the low-dose CT group, the positive predic-
tive value for any positive finding that led to a 
biopsy procedure was 52.9% (265 of 501; 95% 
CI, 48.4 to 57.4), but the positive predictive value 
for positive screening results overall was only 
3.8% (270 of 7181; 95% CI, 3.3 to 4.2) (Table 2). 
The positive predictive value for pulmonary nod-
ules 4 mm or more in the longest diameter was 
3.8% (267 of 7010; 95% CI, 3.4 to 4.3); the value 
increased from 0.5% to 41.3% as the diameter of 
the nodule increased from 4 to 6 mm to more 
than 30 mm. The positive predictive value for 
noncalcified hilar or mediastinal adenopathy 
was 18.5% (51 of 276; 95% CI, 14.1 to 23.4). 
Overall, with low-dose CT, the negative predic-
tive value was 99.9% (19,043 of 19,061; 95% CI, 
99.86 to 99.94).
In the radiography group, the positive predic-
tive value was 70.2% (132 of 188; 95% CI, 64.0 
to 76.8) for a positive screening result that led to 
a biopsy procedure but only 5.7% (136 of 2379; 
95% CI, 4.8 to 6.6) for positive screening results 
overall (Table 2). The positive predictive value for 
pulmonary nodules was 5.8% (123 of 2105; 95% 
CI, 4.9 to 6.9); the value increased from 1.0% to 
39.3% as the diameter of the nodule increased 
from 4 to 6 mm to more than 30 mm. The 
positive predictive value for noncalcified hilar or 
mediastinal adenopathy was 9.3% (8 of 86; 95% 
CI, 3.8 to 15.8). Overall the negative predictive 
value was 99.8% (23,547 of 23,596; 95% CI, 99.7 
to 99.8).
The positive predictive values for atelectasis 
and consolidation could not be reliably estimat-
ed because, unlike pulmonary nodules 4 mm or 
greater in the longest diameter, these findings 
were not always considered to be positive and, 
even when reported on a positive screening re-
sult, they often coexisted with pulmonary nod-
ules and so may not have determined a positive 
screening test.
Diagnostic Follow-up Procedures
Of the 9578 participants with positive screening 
results, 9397 (98.1%) had completely document-
ed diagnostic follow-up. At least one diagnostic 
procedure was performed in 6369 of 7049 par-
ticipants (90.4%) in the low-dose CT group and 
in 2176 of 2438 participants (92.7%) in the radi-
ography group (Table 3). A total of 5717 partici-
pants (81.1%) and 2010 (85.6%) participants in 
the two groups, respectively, underwent at least 
one follow-up imaging procedure, with chest CT 
performed in 5153 (73.1%) and 1546 (65.8%) and 
18F-fluorodeoxyglucose–positron-emission tomog-
raphy (FDG-PET) performed in 728 (10.3%) and 
179 (7.6%); 155 (2.2%) and 83 (3.5%) underwent 
at least one percutaneous cytologic or biopsy pro-
cedure; 306 (4.3%) and 107 (4.6%) underwent at 
least one bronchoscopy (with or without trans-
bronchial biopsy); and 297 (4.2%) and 121 (5.2%) 
underwent at least one diagnostic surgical proce-
dure. In the low-dose CT group, thoracoscopy 
was performed in 44 participants with true pos-
itive results and in 38 participants with false 
positive results. In the radiography group, tho-
racoscopy was performed in 14 participants and 
8 participants with true positive results and false 
positive results, respectively.
Because some of the imaging procedures were 
performed more than once in the same partici-
pant, a comparison of the total numbers of pro-
cedures in the two groups may best reflect the 
diagnostic burden. In the low-dose CT group, a 
total of 10,313 imaging procedures were per-
formed, including 7288 chest CT examinations, 
as compared with 3657 imaging procedures in 
the radiography group, including 2158 chest CT 
examinations.
Procedure records were collected routinely 
only for participants with a positive screening 
result. However, participants with a negative 
screening result may also have undergone diag-
nostic procedures prompted by the screening re-
sult; thus, the data shown in Table 3 underrepre-
sent the total number of procedures prompted 
by the screening examination.
Stage, Histologic Features, and Treatment  
of Lung Cancer
There were 292 cases of diagnosed lung cancer in 
the low-dose CT group and 190 in the radiogra-
phy group, with the difference nearly completely 
accounted for by the higher incidence of stage IA 
cancer in the low-dose CT group (132 cases, vs. 
46 in the radiography group). Table 4 shows the 
characteristics of the diagnosed lung cancers. 
There was no significant difference in the total 
number of lung cancers in stages IIB through IV 
between the low-dose CT group and the radiog-
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raphy group (120 vs. 112). There were many more 
bronchioloalveolar carcinomas and adenocarci-
nomas in the low-dose CT group than in the ra-
diography group (38 vs. 8 and 123 vs. 71, respec-
tively), but the frequencies of other histologic 
features were similar in the two groups. More 
patients with lung cancer were treated with some 
combination of surgery, chemotherapy, and ra-
diotherapy in the low-dose CT group than in the 
radiography group (277 vs. 181), but stage IA 
cancers that were treated only with surgery ac-
counted for most of the difference (117 such can-
cers in the low-dose CT group vs. 40 in the radi-
ography group) (Table 2 in the Supplementary 
Appendix). Only 10 patients in the low-dose CT 
group and 6 patients in the radiography group 
Table 3. Diagnostic Follow-up of Positive Screening Results among the 9397 Patients with Data, According to Study 
Group and Lung-Cancer Status.*
Follow-up Low-Dose CT Chest Radiography
Confirmed Lung Cancer†
Total 












Any diagnostic follow-up 270 (100) 6099 (90.0) 6369 (90.4) 136 (100) 2040 (92.2) 2176 (92.7)
Clinical evaluation 248 (91.9) 4841 (71.4) 5089 (72.2) 117 (86.0) 1297 (58.6) 1414 (60.2)
Imaging studies 258 (95.6) 5459 (80.5) 5717 (81.1) 136 (100) 1874 (84.7) 2010 (85.6)
Chest radiography 112 (41.5) 1172 (17.3) 1284 (18.2) 63 (46.3) 804 (36.3) 867 (36.9)
Chest CT 181 (67.0) 4972 (73.3) 5153 (73.1) 131 (96.3) 1415 (64.0) 1546 (65.8)
FDG-PET or FDG-PET and CT 171 (63.3) 557 (8.2) 728 (10.3) 90 (66.2) 89 (4.0) 179 (7.6)
Percutaneous cytologic analysis or 
biopsy
98 (36.3) 57 (0.8) 155 (2.2) 66 (48.5) 17 (0.8) 83 (3.5)
Transthoracic 77 (28.5) 43 (0.6) 120 (1.7) 54 (39.7) 13 (0.6) 67 (2.9)
Extrathoracic 23 (8.5) 16 (0.2) 39 (0.6) 16 (11.8) 4 (0.2) 20 (0.9)
Bronchoscopy 158 (58.5) 148 (2.2) 306 (4.3) 76 (55.9) 31 (1.4) 107 (4.6)
With neither biopsy nor cytologic 
analysis
84 (31.1) 42 (0.6) 126 (1.8) 34 (25.0) 11 (0.5) 45 (1.9)
With biopsy or cytologic analysis 86 (31.9) 108 (1.6) 194 (2.8) 51 (37.5) 23 (1.0) 74 (3.2)
Surgical procedure 207 (76.7) 90 (1.3) 297 (4.2) 96 (70.6) 25 (1.1) 121 (5.2)
Mediastinoscopy or mediasti- 
notomy
48 (17.8) 12 (0.2) 60 (0.9) 22 (16.2) 0 22 (0.9)
Thoracoscopy 44 (16.3) 38 (0.6) 82 (1.2) 14 (10.3) 8 (0.4) 22 (0.9)
Thoracotomy 156 (57.8) 41 (0.6) 197 (2.8) 78 (57.4) 18 (0.8) 96 (4.1)
Other procedure 46 (17.0) 122 (1.8) 168 (2.4) 17 (12.5) 38 (1.7) 55 (2.3)
* Numbers refer to the number of participants with a positive screening result who underwent any diagnostic procedure 
at least once. Not included are participants with a positive screening result for whom information on diagnostic proce-
dures was incomplete (142 in the low-dose CT group and 39 in the radiography group). Diagnostic procedures were de-
fined as follows: clinical evaluation (evaluation during an outpatient visit — physical examination, pulmonary-function 
testing, sputum cytologic assessment, or comparison of screening results with historical images), chest CT (diagnostic, 
low-dose, or limited-anatomy chest CT, with or without concurrent CT examination of the abdomen, pelvis, head and 
neck, or brain), fluorodeoxyglucose–positron-emission tomography (FDG-PET) CT (F-18 or fusion), extrathoracic percu-
taneous cytology or biopsy (extrathoracic lymph-node biopsy or percutaneous biopsy of liver, adrenal, or other extratho-
racic tissue), thoracoscopy (with or without biopsy), or other procedures (other cytologic or biopsy procedures, proce-
dures coded as “unknown,” and procedures other than those listed by name on data-collection forms).
† The participants with confirmed lung cancer do not include the 8 participants who were ineligible for the initial screening 
because of a prior lung-cancer diagnosis and 76 participants who received a diagnosis of lung cancer during the initial-
screening year (9 who did not undergo screening and 67 with a negative screening result). “No” denotes lung cancer 
that was not confirmed because of a negative diagnostic result or an unknown reference standard.
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received no treatment at all. However, for each 
cancer stage, the relative frequencies of treat-
ment types did not differ significantly between 
the two screening groups (Table 1 in the Supple-
mentary Appendix).
Discussion
We report the prevalence of abnormalities in the 
NLST population at the onset of screening.8 As 
expected, more positive screening results, more 
diagnostic procedures, more biopsies and other 
invasive procedures, and more lung cancers were 
seen in the low-dose CT group than in the radi-
ography group during the first screening round. 
In addition, more early-stage lung cancers, but 
similar numbers of late-stage cancers, were diag-
nosed in the low-dose CT group.
Our findings for screening with the use of 
low-dose CT are similar to those in previous large 
studies of low-dose CT screening (Early Lung 
Cancer Action Project [ELCAP],22 International 
Early Lung Cancer Action Program [I-ELCAP],23 
Mayo,24 Milano,25 Lung Screening Study Feasibil-
ity Phase,26 Pittsburgh,27 and NELSON [Current 
Controlled Trials number, ISRCTN63545820]28). 
The ages and smoking histories of our partici-
pants were similar to those of participants in 
most of these studies. In addition, the sensitivity 
(93.8%), specificity (73.4%), rate of positive 
screening results (27.3%), and positive predictive 
value (3.8%) of low-dose CT were in the midrange 
of the corresponding values in the previous stud-
ies, as was the proportion of participants who 
underwent biopsy (1.9%).
Two additional findings suggest that screen-
ing by means of low-dose CT was well imple-
mented in our study. The compliance rate of 
98.5% was much higher than the 85% rate that 
was assumed for each screening round in our 
sample-size calculation, and only four of the low-
dose CT scans were judged to be nondiagnostic.
The high rate of positive screening results 
(and the low positive predictive value) with low-
dose CT resulted in the performance of many 
diagnostic procedures. Nonetheless, the number 
of follow-up chest CT scans per positive screen-
ing result in the low-dose CT group was modest 
— approximately 1 scan per positive screening 
result (i.e., 7288 CT scans performed per 7049 
participants with a positive result of low-dose 
CT scanning). A recent cost-effectiveness analy-
sis of lung-cancer screening29 assumed, for the 
baseline case, that nodules 4 to 8 mm (presum-
ably in the longest diameter) would be evaluated 
by means of serial CT at 3, 6, and 9 months, on 
the basis of the protocol for the Mayo study,30 
which started in 1999. Subsequent reports have 
recommended less frequent follow-up CT, as re-
flected in our trial, which should improve the 
cost-effectiveness of the procedure in the face of 
its high rate of positive results.
Some of our findings with respect to the ini-
tial low-dose CT screening are not fully consis-
tent with those reported previously. The preva-
lence of lung cancer (1.1%) is at the low end of 
the reported range in prior large studies of par-
ticipants with similar smoking histories (1.0 to 
2.8%) but is close to the rate of 1.0% in the 
NELSON trial, the most recent study that is com-
parable to ours. This low rate may be due to 
some combination of the following factors: the 
healthy-volunteer effect (volunteers in trials are 
healthier than the general population), a young-
er population in our study than in the most re-
cent studies, the high proportion of former 
smokers in our study, and the limitations of 
lung-cancer prediction estimates that are based 
on pack-years.31 The proportion of all lung can-
cers classified as stage I (55%) was also low 
relative to the range reported in other studies 
(54 to 85%), but this may be partly due to exclu-
sion of small-cell cancer in the other studies and 
the more frequent use of PET-CT to ascertain the 
cancer stage in our study. Adenocarcinoma was 
the most common histologic finding in both our 
study and previous studies. Bronchioloalveolar 
carcinoma occurred about twice as frequently in 
our study (with a rate of 13%) than in others, 
possibly because of higher spatial resolution of the 
screening procedure and more frequent report-
ing of this type of carcinoma. Bronchioloalveolar 
carcinoma is no longer reported in many cen-
ters, on the basis of recent recommendations,32 
and may soon be only of historical interest.
The results of chest radiography in our study 
were also similar to those in the comparable 
subgroup of participants in the PLCO radiogra-
phy group.10 In our radiography group and the 
PLCO radiography subgroup, 9.2% and 11.0% of 
participants, respectively, had positive screening 
results; 0.7% and 0.8% underwent biopsy; and 
0.5% and 0.6% had lung cancer detected on 
screening; the sensitivity in the respective groups 
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 25, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 368;21 nejm.org may 23, 20131990
was 74% and 77%, the specificity was 91% and 
90%, and the positive predictive value was 5.7% 
and 5.5%. These similarities suggest that more 
important outcomes, including mortality from 
lung cancer, should also be similar.
Several limitations of our study deserve dis-
cussion. Our participants were similar to the 
general population of smokers in the United 
States except for a higher proportion of former 
smokers and a higher educational level, which 
may partly explain the lower prevalence of lung 
cancer in our study than in other studies. This 
suggests that caution should be used in general-
izing other results of the initial round of screen-
ing in our study to the U.S. population of 
smokers. In addition, because the numbers of 
follow-up procedures were counted only in par-
ticipants with positive screening results, they un-
doubtedly underestimate the frequency of diagnos-
tic procedures performed because of a screening 
result (e.g., procedures performed to investigate 
potentially clinically significant abnormalities). 
Finally, because mortality was not reduced by 
screening with chest radiography among the 
PLCO participants who were comparable to our 
participants,10 the anticipated comparison of 
the results of our first round of low-dose CT 
screening with no screening in the ongoing 
NELSON trial should be of great in terest.
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